TY - JOUR
TI - Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek
Patients with Inflammatory Bowel Disease
AU - Orfanoudaki, Eleni
AU - Zacharopoulou, Eirini
AU - Kitsou, Vassiliki and
AU - Karmiris, Konstantinos
AU - Theodoropoulou, Angeliki
AU - Mantzaris,
AU - Gerassimos J.
AU - Tzouvala, Maria
AU - Michopoulos, Spyridon
AU - Zampeli,
AU - Evanthia
AU - Michalopoulos, Georgios
AU - Karatzas, Pantelis
AU - Viazis,
AU - Nikos
AU - Liatsos, Christos
AU - Bamias, Giorgos
AU - Koutroubakis,
AU - Ioannis E.
AU - Hellen Grp Study IBD
JO - Journal of Clinical Medicine Research
PY - 2022
VL - 11
TODO - 3
SP - null
PB - MDPI
SN - 1918-3003, 1918-3011
TODO - 10.3390/jcm11030641
TODO - COVID-19; Crohn's disease; vaccine; ulcerative colitis
TODO - Since inflammatory bowel disease (IBD) patients were excluded from
vaccine authorization studies, limited knowledge exists regarding
perceptions and unfavorable effects of COVID-19 vaccination in this
group. We aimed to investigate the real-world use and adverse events
(AEs) of COVID-19 vaccines in Greek IBD patients. Fully vaccinated IBD
patients followed in Greek centers were invited to participate. All
patients filled out an anonymous online survey concerning the
vaccination program, which included information regarding demographics,
clinical characteristics, treatment, vaccination perceptions and
potential AEs. Overall, 1007 IBD patients were included. Vaccine
hesitancy was reported by 49%. Total AEs to vaccination were reported
by 81% after dose 1 (D1) and 76% after dose 2 (D2), including isolated
injection site reactions (36% and 24% respectively). Systemic AEs were
more common after D2 (51%, D2 vs. 44%, D1, p < 0.0001). Very few
patients reported new onset abdominal symptoms (abdominal pain 4% (D1),
6% (D2) and diarrhea 5% (D1), 7% (D2)). There were no serious AEs
leading to emergency room visit or hospitalization. In multivariate
analysis, AEs occurrence was positively associated with young age and
female gender (p < 0.0005 for both doses), whereas inactive disease was
negatively associated with AE in D1 (p = 0.044). SARS-CoV-2 vaccination
in Greek IBD patients demonstrated a favorable and reassuring safety
profile.
ER -